Dear colleagues, dear friends,
First of all, thank you very much for your participation in the TREOCAPA study.
At the start of this trial, we sent you a questionnaire on the management of persistent ductus arteriosus and neurodevelopmental follow-up in your center. The results of the trial are have been shared with all the investigating centers and the article accepted by JAMA Pediatrics is slated for April 2026 print and the February 16 Online First issue.
As we announced in the recent webinaire meeting with investigators of the TREOCAPA and TREOCAPA LT studies (2026/01/14), we send you now a questionnaire that will assess the impact of the trial results on daily medical practice.
We sincerely thank you for the time spent answering this questionnaire. It includes 32 questions and requires about 30-45 minutes to answer. Do not hesitate to contact us to clarify certain questions if necessary.
Gilles Cambonie, MD, PhD
Department of neonatal Medicine, Montpellier University Hospital Center, France
Andrei Morgan, FRCPCH, MSc, PhD (Epidemiology / Neonatology)
INSERM UMR 1153, Paris, France
Jean-Christophe Rozé, MD, PhD
Coordinator of the European TREOCAPA study
Jennifer Zeitlin
Coordinator of the European TREOCAPA-LT study